Abstract
The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.
MeSH terms
-
Anaplastic Lymphoma Kinase
-
Animals
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Dogs
-
Humans
-
Macaca fascicularis
-
Male
-
Neoplasms / drug therapy*
-
Protein Kinase Inhibitors / chemical synthesis*
-
Protein Kinase Inhibitors / pharmacokinetics
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines / chemical synthesis*
-
Pyrimidines / pharmacokinetics
-
Pyrimidines / therapeutic use
-
Rats
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Structure-Activity Relationship
-
Sulfones / chemical synthesis*
-
Sulfones / pharmacokinetics
-
Sulfones / therapeutic use
-
Xenograft Model Antitumor Assays
Substances
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Sulfones
-
ALK protein, human
-
Alk protein, rat
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases
-
ceritinib